NASDAQ:ABMD - ABIOMED Stock Price, Price Target & More

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED, Inc. (NASDAQ:ABMD) issued its quarterly earnings results on Thursday, May, 3rd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.16. The medical equipment provider had revenue of $174.44 million for the quarter, compared to analyst estimates of $164.30 million. ABIOMED had a return on equity of 17.58% and a net margin of 18.89%. The business's revenue for the quarter was up 39.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.33 EPS. View ABIOMED's Earnings History.

ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for ABIOMED.

8 equities research analysts have issued 1-year target prices for ABIOMED's stock. Their predictions range from $280.00 to $480.00. On average, they anticipate ABIOMED's share price to reach $363.1429 in the next year. This suggests that the stock has a possible downside of 13.4%. View Analyst Ratings for ABIOMED.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to ABIOMED include Becton Dickinson and (BDX), Stryker (SYK), Boston Scientific (BSX), FRESENIUS SE &/S (FSNUY), Baxter International (BAX), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), ICU Medical (ICUI), Hill-Rom (HRC), Globus Medical (GMED), Insulet (PODD), Haemonetics (HAE), Penumbra (PEN) and Cantel Medical (CMD).

News coverage about ABMD stock has been trending somewhat negative on Monday, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. ABIOMED earned a media sentiment score of -0.06 on Accern's scale. They also assigned media coverage about the medical equipment provider an impact score of 47.53 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

ABIOMED's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.76%), Bank of Montreal Can (0.06%), Dorsey Wright & Associates (0.06%), Gulf International Bank UK Ltd (0.03%), Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%) and Handelsbanken Fonder AB (0.02%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

ABMD stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Dorsey Wright & Associates, Handelsbanken Fonder AB, Juncture Wealth Strategies LLC, Empowered Funds LLC and YHB Investment Advisors Inc.. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Insider Buying and Selling for ABIOMED.

ABMD stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Gulf International Bank UK Ltd, Fjarde AP Fonden Fourth Swedish National Pension Fund, NN Investment Partners Holdings N.V., State of Alaska Department of Revenue, Xact Kapitalforvaltning AB, IFM Investors Pty Ltd and Gateway Investment Advisers LLC. View Insider Buying and Selling for ABIOMED.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ABMD stock can currently be purchased for approximately $419.38.

ABIOMED has a market capitalization of $18.69 billion and generates $593.75 million in revenue each year. The medical equipment provider earns $112.17 million in net income (profit) each year or $2.45 on an earnings per share basis. ABIOMED employs 1,143 workers across the globe.

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]